Notice of first launch, interruption or termination of supply of a human drug
 Date ▲HolderCodeDrugDate fromSubject
 4.9.2023Viatris Healthcare Limited (VIM-1)86085Thioctacid 600 HR (tbl flm 30x600 mg (liek.skl.hnedá))4.9.2023O
 4.9.2023GlaxoSmithKline Biologicals S.A. (GAG)25092ENGERIX-B 20 µg (sus inj 1x1 ml (striek.inj.skl.napln.))1.9.2023R
 4.9.2023B.Braun Melsungen AG (BME)76566Metronidazol B. Braun 5 mg/ml (sol inf 20x100 ml/500 mg (fľ. PE))4.9.2023O
 4.9.2023Sanofi Winthrop Industrie (SWI-11)15413Calcium Resonium (plu pre 1x300 g (nádobka plastová))15.9.2023R
 1.9.2023Fresenius Kabi s.r.o. (FRK-CZ-3)37752Sodium chloride Fresenius Kabi 0,9 % (sol inf 20x250 ml (fľ.LDPE - KabiPac))1.9.2023O
 31.8.2023medac Gesellschaft für klinische Spezialpräparate m.b.H. (MED-2)1074EVinorelbine medac 20 mg mäkké kapsuly (cps mol 1x20 mg (blis.PVC/PVDC/Al))1.9.2023U
 31.8.2023medac Gesellschaft für klinische Spezialpräparate m.b.H. (MED-2)1076EVinorelbine medac 30 mg mäkké kapsuly (cps mol 1x30 mg (blis.PVC/PVDC/Al))1.9.2023U
 31.8.2023Fresenius Kabi s.r.o. (FRK-CZ-3)2567DAnidulafungin Fresenius Kabi 100 mg (plc ifc 1x100 mg (liek.inj.skl.))31.8.2023R
 31.8.2023Fresenius Kabi s.r.o. (FRK-CZ-3)58629NUTRAMIN VLI (sol inf 10x500 ml (fľ.skl.inf.))31.8.2023O
 31.8.2023B.Braun Melsungen AG (BME)13902Chlorid sodný B. Braun 0,9 % infúzny roztok (sol inf 10x500 ml (fľ.PE))28.8.2023R
 31.8.2023GlaxoSmithKline Biologicals S.A. (GAG)25980HAVRIX 1440 Dosis adulta (sus inj 1x1 ml/1440 E.U. (striek.inj.skl.napln.s ihlou))1.9.2023R
 31.8.2023KRKA, d.d., Novo mesto (KRK-2)89663Nolpaza 40 mg prášok na injekčný roztok (plv ino 10x40 mg (liek.inj.skl.))4.9.2023O
 31.8.2023B.Braun Melsungen AG (BME)5147DAmpres 10 mg/ml (sol inj 10x5 ml (amp.skl.))31.8.2023Z
 30.8.2023Obvius Investment B.V. (OBV)9164CCarmustine Obvius 100 mg prášok a rozpúšťadlo na infúzny koncentrát (plc fol 1x100 mg+1x3 ml solv. (liek.inj.skl.))24.8.2023U
 30.8.2023Merck Sharp & Dohme B.V. (MSD-NL)95505VARIVAX (plv iul 1x3 ml inj.l.s pr.(min.1350 PFU/ 0,5 ml)+1x1 ml nap.i.s.+2 ihly)4.9.2023R

Subject means:
U-Placement of medicine to Slovakian market, R-Discontinuation of medicine supply to Slovakian market,
O-Resumption of medicine supply to Slovakian market, Z-Cancelation of medicine supply to Slovakian market


Date from
From
To



 
Processed by the system MCR.Prerusenie (8.0)